Table 4.
Incidence of specific fatal adverse events (grade 5) in included studies (not included ASCO meeting abstracts).
| Fatal adverse events | Study | Total Events (%) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tawbi | Omuro | Motzer | Long | Hellmann | D’Angelo | Wolchok | Hellmann | Hammers | Hodi | Antonia | Wolchok | ||
| Cardiac disorders | 7 (0.32) | ||||||||||||
| Myocarditis | 1 | 1 | 2 | ||||||||||
| Autoimmune Myocarditis | 1 | 1 | |||||||||||
| Ventricular Arrhythmia | 1 | 1 | |||||||||||
| Cardiac Insufficiency | 1 | 1 | |||||||||||
| Cardiac Tamponade | 1 | 1 | |||||||||||
| Circulatory Collapse | 1 | 1 | |||||||||||
| Respiratory | 8 (0.36) | ||||||||||||
| Pneumonitis | 1 | 3 | 1 | 0;1 | 6 | ||||||||
| Immune-mediated Bronchitis | 1 | 1 | |||||||||||
| Lung Infection | 1 | 1 | |||||||||||
| Hepatic | 2 (0.09) | ||||||||||||
| Liver Toxic Effect | 1 | 1 | |||||||||||
| Liver Necrosis | 1 | 1 | |||||||||||
| Renal | 2 (0.09) | ||||||||||||
| Acute Tubular Necrosis | 1 | 1 | |||||||||||
| Renal Failure | 1;0 | 1 | |||||||||||
| Endocrine | 2 (0.09) | ||||||||||||
| Panhypopituitarism | 1 | 1 | |||||||||||
| Gastrointestinal | 2 (0.09) | ||||||||||||
| Lower Gastrointestinal Hemorrhage | 1 | 1 | |||||||||||
| Hematologic | 2 (0.09) | ||||||||||||
| Aplastic Anemia | 1 | 1 | |||||||||||
| The Hemophagocytic Syndrome | 1 | 1 | |||||||||||
| Other | 2 (0.09) | ||||||||||||
| Sudden Death | 1 | 1 | |||||||||||
| Myasthenia Gravis | 1;0 | 1 | |||||||||||
This table only demonstrated the fatal adverse events reported by the included studies.